We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Arcutis Biotherapeutics, Inc. (ARQT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Arcutis Biotherapeutics, Inc. is one of 1000 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Arcutis Biotherapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ARQT's full-year earnings has moved 49.2% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ARQT has gained about 3.7% so far this year. At the same time, Medical stocks have lost an average of 4.8%. This means that Arcutis Biotherapeutics, Inc. is performing better than its sector in terms of year-to-date returns.
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 31.7%.
The consensus estimate for Chugai Pharmaceutical Co., Ltd. Unsponsored ADR's current year EPS has increased 18.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Arcutis Biotherapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 508 individual stocks and currently sits at #79 in the Zacks Industry Rank. On average, stocks in this group have lost 5.8% this year, meaning that ARQT is performing better in terms of year-to-date returns.
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR, however, belongs to the Medical - Drugs industry. Currently, this 162-stock industry is ranked #59. The industry has moved -2.2% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Arcutis Biotherapeutics, Inc. and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Arcutis Biotherapeutics, Inc. (ARQT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Arcutis Biotherapeutics, Inc. is one of 1000 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Arcutis Biotherapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ARQT's full-year earnings has moved 49.2% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ARQT has gained about 3.7% so far this year. At the same time, Medical stocks have lost an average of 4.8%. This means that Arcutis Biotherapeutics, Inc. is performing better than its sector in terms of year-to-date returns.
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 31.7%.
The consensus estimate for Chugai Pharmaceutical Co., Ltd. Unsponsored ADR's current year EPS has increased 18.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Arcutis Biotherapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 508 individual stocks and currently sits at #79 in the Zacks Industry Rank. On average, stocks in this group have lost 5.8% this year, meaning that ARQT is performing better in terms of year-to-date returns.
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR, however, belongs to the Medical - Drugs industry. Currently, this 162-stock industry is ranked #59. The industry has moved -2.2% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Arcutis Biotherapeutics, Inc. and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR as they could maintain their solid performance.